1D-myo-inosose-3 | 56816-02-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1D-myo-inosose-3
• 英文别名: 2L-2,3,5³4,6-Inosose；D-myo-Inosose-(1)；(2S)-2r,3c,4t,5c,6t-pentahydroxy-cyclohexanone；(2S)-2r,3c,4t,5c,6t-Pentahydroxy-cyclohexanon
• CAS: 56816-02-5
• 化学式: C₆H₁₀O₆
• 分子量: 178.142
• InChiKey: VYEGBDHSGHXOGT-REJXVDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.63
• 重原子数：
  12.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  118.22
• 氢给体数：
  5.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1D-myo-inosose-3 在 platinum(IV) oxide 硫酸 、 氢气 作用下， 生成 (-)-1L-Cyclohexane-1,3/2,4-tetrol
  参考文献：
  名称：

  Cyclitols and their Methyl Ethers. III. Catalytic Air Oxidation, the Hydrogenolysis of Inososes, and Some Pentol and Tetrol Methyl Ethers^1-3

  摘要：

  DOI：

  10.1021/ja00862a030
• 作为产物：
  描述：

  Inositol 在 2,6-二氯-1,4-苯醌 、 [(2,9-dimethyl-1,10-phenanthroline)-Pd(μ-OAc)]₂(OTf)₂ 作用下， 以 二甲基亚砜 为溶剂， 反应 4.5h， 生成 1D-myo-inosose-3
  参考文献：
  名称：

  [EN] SELECTIVE OXIDATION OF CARBOHYDRATES
  [FR] OXYDATION SÉLECTIVE DES GLUCIDES

  摘要：

  该发明涉及碳水化合物化学领域。提供了一种用于对碳水化合物底物中的单个次生羟基功能进行区域选择氧化的方法，该底物包含两个或更多个次生羟基功能，包括将碳水化合物底物在溶剂中与过渡金属催化剂复合物和氧化剂接触以产生单氧化的碳水化合物。

  公开号：

  WO2013191549A1

文献信息

• Synthesis and evaluation of 3-modified 1D-myo-inositols as inhibitors and substrates of phosphatidylinositol synthase and inhibitors of myo-inositol uptake by cells
  作者：Stephen C. Johnson、Jean Dahl、Tzenge Lien Shih、David J. A. Schedler、Laurens Anderson、Thomas L. Benjamin、David C. Baker

  DOI：10.1021/jm00075a018

  日期：1993.11

  evaluated as substrates for phosphatidylinositol synthase and uptake by intact cells. 1D-3-Amino-, -3-chloro-, and -3-(acetylthio)-3-deoxy-myo-inositols were all synthesized by nucleophilic displacement of the 6-O-(trifluoromethyl)sulfonyl group of 1L-1,2:3,4-di-O-cyclohexylidene-5-O-methyl-6-O-[(trifluoromethyl)-sulfon yl] - chiro-inositol (which was prepared from L-quebrachitol), respectively, by reaction

  合成了许多3-取代的1D-肌醇，并将其作为磷脂酰肌醇合酶和被完整细胞摄取的底物进行评估。1D-3-氨基-，-3-氯-和-3-（乙酰硫基）-3-脱氧-肌醇均通过亲核取代1L-1的6-O-（三氟甲基）磺酰基合成，通过与LiN3反应分别形成2：3,4-二-O-环己叉基-5-O-甲基-6-O-[（三氟甲基）-磺酰基]-手性肌醇，然后还原叠氮基官能团，并与LiCl和KSAc结合，得到O保护的化合物。使用BBr3进行O-脱甲基和伴随的乙缩醛水解提供了游离羟基的3-氨基-和3-氯-3-脱氧-1D-肌醇。3-巯基类似物是通过除去乙酰硫基类似物的缩醛基获得的，然后进行过乙酸的乙酰化和纯化，然后进行O-脱甲基和脱乙酰。通过Barton-McCombie脱氧从6-O-（咪唑-1-基硫代羰基）化合物合成3-脱氧衍生物。通过叠氮化物置换，由1L-1-O-甲苯磺酰基-手性肌醇直接合成3-叠氮基衍生物。3-酮类似物是通
• 1-FLUORO-1-DEOXY-SCYLLO-INOSITOL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Waratah Pharmaceuticals, Inc.

  公开号：EP1940373B1

  公开（公告）日：2015-05-06
• Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
  申请人：Cruz Antonio

  公开号：US20070111970A1

  公开（公告）日：2007-05-17

  Inositol derivatives are described that are represented by the structural formula I wherein X is a radical of scyllo-inositol wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl, or carboxamide and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl, or pharmaceutically acceptable salts thereof. The compounds, compositions comprising same and methods using same are described for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence.
• SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE
  申请人：Cruz Antonio

  公开号：US20090170957A1

  公开（公告）日：2009-07-02

  Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, ammo, lmmo, azido, thiol, thioalkyl, thioaryl, mtro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl or carbamide, or pharmaceutically acceptable salts thereof. Said derivatives and compositions comprising the same are useful in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence.
• Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence
  申请人：Curz Antonio

  公开号：US20100105631A1

  公开（公告）日：2010-04-29

  Inositol derivatives are described that are represented by the structural formula I wherein X is a radical of scyllo-inositol wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl, or carboxamide and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl, or pharmaceutically acceptable salts thereof. The compounds, compositions comprising same and methods using same are described for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence.